Future therapy for non-alcoholic fatty liver disease

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent cause of chronic liver disease, potentially progressing to cirrhosis and hepatocellular carcinoma.
• NAFLD significantly increases risks for cardiovascular and cancer-related mortality.
• Its development involves hepatic metabolic stress, insulin resistance, oxidative stress, and inflammatory pathways.

Purpose of the Study:

• To review current therapeutic strategies for non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD.
• To summarize ongoing research and clinical trials for novel NASH treatments.
• To highlight the expected timeline for the first approved NASH therapies.

Main Methods:

• Review of current literature and clinical trial data on NASH treatments.
• Analysis of therapeutic targets including metabolic improvement, cell stress reduction, apoptosis inhibition, and anti-inflammatory/anti-fibrotic approaches.
• Assessment of the pipeline for agents in pivotal trials.

Main Results:

• Multiple therapeutic agents targeting key NASH pathways are in late-stage clinical development.
• Current treatment strategies focus on addressing the multifaceted pathogenesis of NASH.
• No therapies are currently approved, but the landscape is rapidly evolving.

Conclusions:

• The first approved therapies for NASH are anticipated within the next 2-3 years.
• These new treatments offer hope for managing this widespread liver disease.
• Advancements target critical pathways involved in NASH progression, aiming to reduce morbidity and mortality.